To evaluate survival and quality-of-life outcomes from 10 to 17 years following pelvic exenteration.
Key Findings:
33% of 273 patients survived beyond 10 years post-surgery.
Median overall survival was 4.8 years.
Survival rates were 48.4%, 35.1%, and 31.5% at 5, 10, and 15 years respectively.
Quality of life scores showed improvement over the first 18 months and maintained thereafter.
Interpretation:
Pelvic exenteration demonstrates promising long-term survival and quality-of-life outcomes, supporting its use as a curative treatment for selected patients with advanced pelvic malignancies, highlighting the need for further research.
Limitations:
Limited number of patients completing surveys beyond 10 years may affect the reliability of quality of life measures.
Potential biases in self-reported quality of life measures.
Conclusion:
Pelvic exenteration can lead to significant long-term survival and quality of life improvements, warranting its consideration as a viable treatment option for advanced pelvic cancer.
by Daniel Steffens, Michael J Solomon, Sascha Karunaratne, Kilian Brown, Bora Kim, Peter Lee, Kirk Austin, Christopher Byrne, Lilian Whitehead, Cherry Koh
The Eugene M. & Christine E. Lynn Cancer Institute at Boca Raton Regional Hospital, part of Baptist Health, reached an important milestone in the advancement of cancer care with the successful treatment of its first patient utilizing proton therapy, according to physicians at both the Institute and the hospital.
